Evidence map›Paper›PMID 41619160›Full record

ArticleJournal of endocrinological investigation2026

Influence of hormonal levels on atherosclerotic risk markers and platelet activation related to diabetic complications in patients with type 1 diabetes.

Evangelia Baldimtsi, Bertil Ekman, Per A Whiss, Jeanette Wahlberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Evangelia BaldimtsiDepartment of Activity and Health, and Department of Health, Medicine and Caring Sciences, Linköping University Hospital, Linköping University, Linköping, Sweden. evangelia.baldimtsi@liu.se.ORCID http://orcid.org/0000-0002-4433-1376
Bertil EkmanDepartment of Endocrinology in Linköping and Norrköping, and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.ORCID http://orcid.org/0000-0001-8732-7361
Per A WhissDepartment of Biomedical and Clinical Sciences, Division of Clinical Chemistry and Pharmacology, Linköping University, Linköping, Sweden.ORCID http://orcid.org/0000-0003-3184-0427
Jeanette WahlbergFaculty of Medical Sciences, Örebro University, Örebro, Sweden.ORCID http://orcid.org/0000-0003-4061-6830

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsPatients with childhood-onset type 1 diabetes (T1D) are at increased risk of developing microvascular complications, including neuropathy and nephropathy. Hormonal dysregulation and markers of atherosclerotic plaque instability and platelet activation may play key roles in the pathogenesis of these complications. The aim of this study was to investigate the impact of hormonal levels on atherosclerotic risk markers and platelet function, as well as to explore the association between diabetic neuropathy and nephropathy in individuals with childhood-onset type 1 diabetes.

methodsIn this cross-sectional analysis of a longitudinal cohort, 34 individuals with childhood-onset type 1 diabetes (mean age 27.6 ± 4.2 years; diabetes duration 8.2 ± 5.6 years) were examined. S-IGF-I, long-term HbA1c, micro/macroalbuminuria, triiodothyronine and thyroxine, S-Cortisol, P-ACTH, P-Renin, sP-Selectin, P-MMP-9, P-TIMP-1, P-Adiponectin, and platelet adhesion to albumin, collagen, and fibrinogen were assessed. An abnormality in nerve conduction tests was defined as diabetic neuropathy.

resultsS-IGF-I was negatively correlated with age (r = -0.36, p = 0.007), and with long-term HbA1c (r = -0.426, p = 0.019, corrected for age). IGF-I levels in patients diagnosed with clinical neuropathy (n = 6) were lower (123 ± 38 µg/L) than in patients without neuropathy (n = 26, 178 ± 56 µg/L, p = 0.029). S-IGF-I levels were also lower in patients with nephropathy (n = 7, 122 ± 28 µg/L) compared with patients without nephropathy (n = 27, 180 ± 60 µg/L, p = 0.02). S-IGF-I was negatively correlated with P-TIMP-1 (r = -0.44, p = 0.009), sP-Selectin (r = -0.53, p = 0.001), and positively correlated with platelet adhesion to fibrinogen (r = 0.38, p = 0.035). S-free-Triiodothyronine correlated negatively with P-MMP-9, (r = -0.46, p = 0.005), and P-MMP-/P-TIMP-1 ratio (r = -0.40, p = 0.018), and P-Adiponectin (r = -0.49, p = 0.018). P-Renin correlated negatively with P-Adiponectin (r = -0.34, p = 0.045).

conclusionsLow serum IGF-I levels were associated with the presence of diabetic neuropathy and nephropathy in young adults with type 1 diabetes. Additionally, both IGF-I and S-free-Triiodothyronine levels were linked to changes in platelet activation and atherosclerotic markers, suggesting that hormonal dysregulation may contribute to early vascular complications in this population.

Indexed as

AtherosclerosisBiomarkersDiabetes ComplicationsDiabetes Mellitus, Type 1Platelet ActivationAdultCross-Sectional StudiesDiabetic NeuropathiesFemaleHumansInsulin-Like Growth Factor ILongitudinal StudiesMaleRisk FactorsYoung AdultBiomarkersInsulin-Like Growth Factor IAdiponectinDiabetes mellitus type 1Diabetic neuropathyInsulin-like growth factor IMatrix metalloproteinase 9Platelet adhesivenessReninTissue inhibitor of metalloproteinase-1

Identifiers

PMID41619160
PMCPMC13219068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.